Lab Information
Waqqas Afif (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoringResearch Interests
My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.Team Members
| Name | Position |
|---|
Latest Publications
- Avinashi, V., Gupta, M., Payne, B. A., Amhaz, H., Temirova, A. T., Afif, W., Ashok, D., Barkey, J., Burnett, D., Bush, J. W., Cameron, S., Carr, S., Demellawy, D. E., Erdle, S., Huynh, H. Q., Griffin, J., Grover, S. C., Grzywacz, K., Jeimy, S., Ko, H. H., Lacuesta, G., Marcon, M., Mayrand, S., Petropolis, H., Rodrigues, D., Sherlock, M., Song, C., Tardio, N., Vander Leek, T. K., Vurzinger, M., Williams, B. A., Xenodemetropoulos, T., Ma, C. & Chan, E. S. (2025). Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, vol. 21, p. 47.
- Ongay, J., Candel, I., Bitton, A., Afif, W., Bessissow, T. & Lakatos, P. L. (2025). Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare - the Double-Edged Sword. Case reports in gastroenterology, vol. 19, p. 637-643.
- Drügg Hahn, G., Lakatos, P. L., Maedler-Kron, C., Marcus, V., Afif, W., Wild, G., Bitton, A., Flores, C., de Magalhães Francesconi, C. F. & Bessissow, T. (2025). Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Inflammatory bowel diseases.
- Li Fraine, S., Marcus, V., Kron, C. M., Lakatos, P. L., Afif, W., Bitton, A., Wild, G. & Bessissow, T. (2025). Impact of Individual Colonic Segment Histological Activity on Disease Relapse in Patients with Ulcerative Colitis. Journal of clinical medicine, vol. 14.
- De Marco, D., Heron, V., Bitton, A., Bessissow, T., Lakatos, P., Wild, G. & Afif, W. (2025). Assessing the role of ustekinumab dose escalation in Crohn's disease patients with loss of response: an observational study. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 97-102.
- Sealey, D. C., Ho, K. F., Zhou, Z. C., Clark, M., Feagan, B. G., Panaccione, R., Steinhart, A. H., Bolshtyansky, E., Williamson, M. & Afif, W. (2025). Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data. Canadian journal of gastroenterology & hepatology, vol. 2025, p. 5713315.
- Targownik, L., Afif, W., Singh, S., Siffledeen, J., Ma, C., McHugh, K., Charbonneau, J. & Rioux, L.-C. (2025). Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 21-30.
- Zhen, J., Simoneau, M., Sharma, P., Germain, P., Watier-Levesque, P., Othman, A., Marshall, J. K., Afif, W. & Narula, N. (2024). Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 423-430.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Pedicelli, A. & Afif, W. (2024). In active ulcerative colitis, risankizumab induced and maintained remission. Annals of internal medicine, vol. 177, p. JC127.
See also
